NCT06582732Phase 2Completed

Performance of the Travoprost Intraocular Implant

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-11-02Actual

Enrollment · participants210Actual

Source updated2024-10-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Glaucoma, Open-Angle; Ocular Hypertension

Treatments or interventions studied

Travoprost Intracameral Implant exchanged at Month 12DrugAlso known as iDose TR
Travoprost Intracameral Implant exchanged at Month 3DrugAlso known as iDose TR
Travoprost Intracameral Implant exchanged at Month 6DrugAlso known as iDose TR
Travoprost Intracameral Implant exchanged at Month 24DrugAlso known as iDose TR
Travoprost intracameral implant exchanged at Month 21DrugAlso known as iDose TR
Travoprost intracameral implant exchanged at Month 18DrugAlso known as iDose TR
Travoprost intracameral implant exchanged at Month 15DrugAlso known as iDose TR

Primary outcomes · main study measures

Read the study measures

measure: Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration; description: concentration of travoprost free acid (ng/mL) in the aqueous humor 12 months post-administration as assessed by liquid chromatography tandem mass spectrometry (LC-MS/MS); timeFrame: month 12; measure: Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration; description: concentration of travoprost free acid (ng/mL) in the aqueous humor 3 months post-administration as assessed by LC-MS/MS; timeFrame: month 3; measure: Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration; description: concentration of travoprost free acid (ng/mL) in the aqueous humor 6 months post-administration as assessed by LC-MS/MS; timeFrame: month 6; measure: Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration; description: concentration of travoprost free acid (ng/mL) in the aqueous humor 24 months post-administration as assessed by LC-MS/MS; timeFrame: month 24; measure: Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration; description: concentration of travoprost free acid (ng/mL) in the aqueous humor 21 months post-administration as assessed by LC-MS/MS; timeFrame: month 21; measure: Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration; description: concentration of travoprost free acid (ng/mL) in the aqueous humor 18 months post-administration as assessed by LC-MS/MS; timeFrame: month 18; measure: Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration; description: concentration of travoprost free acid (ng/mL) in the aqueous humor 15 months post-administration as assessed by LC-MS/MS; timeFrame: month 15

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history